Compare Rocket Companies Inc. Class A Common Stock (RKT) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Rocket Companies Inc. Class A Common Stock vs Sanofi SA — how do they compare? Rocket Companies Inc. Class A Common Stock trades at $10.69 (market cap $30.67B), while Sanofi SA trades at $40.51 (market cap $94.58B). The key difference: Sanofi SA is far larger — about 3.1× Rocket Companies Inc. Class A Common Stock's market cap, and Sanofi SA pays a 6.18% dividend while Rocket Companies Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Rocket Companies Inc. Class A Common Stock for 0 Days and Sanofi SA for 94 Days on average.
| RKT | SNY | |
|---|---|---|
Market Cap | $30.67B | $94.58B |
Volume | 41,104,143 | 3,988,460 |
Sector | Financials | Health |
52-Week High | $23.44 | $52.34 |
52-Week Low | $10.53 | $39.12 |
Typical Hold Time | 0 Days | 94 Days |
Enterprise Value | $60.66B | $113.80B |
Dividend Yield | — | 6.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Rocket Companies (RKT) trades at $10.83, down 0.37% on the day, with a neutral technical signal and mixed earnings history. The stock is near its 52-week low amid a challenging mortgage market. Recent financials show a net loss of $68 million in 2025 but project a return to profitability in 2026. Analyst consensus is a 'Buy' with a $16.88 price target, though sentiment is tempered by high interest rates and housing market pressures.
Outlook: RKT offers potential upside from current depressed levels if mortgage demand recovers, but faces significant headwinds from persistent high rates and weak housing activity. Risks include competitive pressures and regulatory scrutiny, while opportunities lie in market share gains and cost management improvements. Investors should weigh the cyclical recovery potential against near-term macroeconomic challenges.
SNY trades at $39.77, up 0.08% on the day, with a bearish technical signal from moving averages but oversold RSI readings. The company reported strong Q2 2026 earnings, beating estimates with EPS of $1.21 versus $1.10 expected, and announced a significant expansion of its immunology alliance with Regeneron, valued up to $8 billion. Revenue for 2025 was $46.72 billion, with net income of $7.81 billion, reflecting a profit margin of 16.72%.
The outlook is mixed; recent collaborations and earnings beats provide growth catalysts, but a projected decline in 2026 net income to $4.0 billion and bearish technical indicators suggest near-term headwinds. Risks include execution of new partnerships and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Rocket Companies Inc. Class A Common Stock
Rocket Companies, Inc. operates a homeownership platform spanning mortgage origination and servicing, real estate, title and closing, and personal finance, with flagship brands including Rocket Mortgage, Rocket Close, Rocket Money, Rocket Loans, and Redfin.
Read more on RKT →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
